Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / PHARMACEUTCL ETF
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
1,861,501
-
Shares change
-
-1,208,875
-
Total reported value, excl. options
-
$97,792,252
-
Value change
-
-$64,452,979
-
Number of buys
-
23
-
Number of sells
-
-27
-
Price
-
$52.51
Significant Holders of VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) as of Q4 2016
65 filings reported holding PPH - VANECK ETF TRUST - PHARMACEUTCL ETF as of Q4 2016.
VANECK ETF TRUST - PHARMACEUTCL ETF (PPH) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,861,501 shares
.
Largest 10 shareholders include GOLDMAN SACHS GROUP INC (550,062 shares), CITIGROUP INC (350,610 shares), JPMORGAN CHASE & CO (252,306 shares), BANK OF AMERICA CORP /DE/ (122,427 shares), UBS Group AG (98,452 shares), MORGAN STANLEY (95,697 shares), RAYMOND JAMES & ASSOCIATES (95,109 shares), MAYO INVESTMENT ADVISERS LLC (45,625 shares), ROYAL BANK OF CANADA (27,898 shares), and STUYVESANT CAPITAL MANAGEMENT (23,820 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.